Tocilizumab as an effective treatment option for idiopathic orbital inflammation: a case report and literature review
International Journal of Ophthalmology · 18.01.2026 · 19 (1) · 199-201
DOI: 10.18240/ijo.2026.01.26 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Ophthalmology, erschienen am 18.01.2026. Verfasst von Hai-Yang Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, …. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- State Key Laboratory of Eye Health, Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.
Zitieren
APA
Zhang, H. Y., Zhang, H. J., & Zhou, H. F. (2026). Tocilizumab as an effective treatment option for idiopathic orbital inflammation: a case report and literature review. International Journal of Ophthalmology, 19(1), 199-201. https://doi.org/10.18240/ijo.2026.01.26
Vancouver
Zhang HY, Zhang HJ, Zhou HF. Tocilizumab as an effective treatment option for idiopathic orbital inflammation: a case report and literature review. International Journal of Ophthalmology. 2026;19(1):199-201. doi:10.18240/ijo.2026.01.26
BibTeX
@article{Zhang2026,
author = {Zhang, Hai-Yang and Zhang, Hui-Jie and Zhou, Hui-Fang},
title = {Tocilizumab as an effective treatment option for idiopathic orbital inflammation: a case report and literature review},
journal = {International Journal of Ophthalmology},
year = {2026},
volume = {19},
number = {1},
pages = {199--201},
doi = {10.18240/ijo.2026.01.26}
}
EUVIMED